Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Auckland cancer drug discovery gets funding boost

Auckland cancer drug discovery gets funding boost


Significant research at the University of Auckland into the discovery and development of new drugs to improve patient outcomes in radiation therapy was one of the high profile research programmes funded in the latest round of Health Research Council grants.

Professor Bill Wilson and his multidisciplinary team from the University-based Auckland Cancer Society Research Centre (ACSRC) were granted nearly $5 million over the next five years to develop new drugs for this neglected setting, and for identifying genetic biomarkers that will match these drugs to patients who will most benefit.

“This grant provides critical support for the overall effort in targeting hypoxia in tumours at the University of Auckland,” says Professor Wilson. Another ACSRC member Associate Professor Adam Patterson also gained funding for two smaller projects in a related area of this research.

The new research programme entitled ‘Biomarker-guided drug targeting of the tumour microenvironment in radiotherapy’ is primarily a drug discovery programme.

“We are looking at taking forward a class of drugs that we understand in detail through Senior Research Fellow Dr Moana Tercel’s medicinal chemistry work, and we expect to be able to identify a clinical candidate in this series in the next year,” says Professor Wilson.

“The programme also involves two early stage drug discovery projects which Associate Professor Michael Hay leads. There is exciting potential here that builds on the understanding that we have developed over some years about targeting hypoxia,” he says.

“The other half of the programme seeks to understand how to identify the patients who will benefit from these drugs. We will be investigating biomarkers that predict which tumours will respond,” says Professor Wilson. “This is a neglected field with great promise.”

“Drug development in the 21st century must move away from huge clinical trials with unselected patients towards targeting drugs to tumours based on their molecular profile.”
The team will focus on head and neck cancers because there is an important need for new drugs in the treatment of these cancers.

“That is the clinical setting where we have the strongest evidence that tumour hypoxia is a major problem,” says Professor Wilson. “Hypoxic tumour cells are not eliminated by conventional radio-therapy, so this is an ideal setting to develop these agents.”

“The key is using our existing knowledge and matching the patient tumour profile with the new drug,” he says. “We know that this is necessary to advance drugs through the clinical development phase.”

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Fonterra: Canpac Site 'Resize' To Focus More On Paediatrics

Fonterra is looking at realigning its packing operations at Canpac, in the Waikato, to focus more on paediatric nutritionals... The proposed changes could mean around 110 roles may not be required at the site which currently employs 330. More>>

ALSO:

Scoop Business: Postie Plus Brand Gets 2nd Chance With Well-Funded Pepkor

The Postie Plus brand is getting a new lease of life after South Africa’s Pepkor bought the failed retailer’s assets out of administration and said it will use its purchasing power to reduce costs of stock and fatten margins. More>>

ALSO:

Warming: Warming Signs From State Of Climate Report

Climate data from air, land, sea and ice in 2013 'reflect trends of a warming planet' -- says the latest State of the Climate report, launched by U.S. and New Zealand scientists. More>>

ALSO:

Scoop Business: Embrace Falling Home Affordability, Says NZIER

Despair over the inability to afford a house is misplaced and should be embraced as an opportunity to invest in more wealth-creating activity, says the principal economist at the New Zealand Institute of Economic Research, Shamubeel Eaqub. More>>

Productivity Commission: NZ Regulation Not Keeping Pace

New Zealand regulators often have to work with out-of-date legislation, quality checks are under strain, and regulatory workers need better training and development. More>>

ALSO:

Callaghan Innovation: Investment To Help Deepen Innovation Reporting

Callaghan Innovation, the government’s high tech HQ for Kiwi business, is to help deepen New Zealand media coverage of the commercialisation of innovation through an arms-length partnership with independent business news service BusinessDesk. More>>

ALSO:

Tax Credits, Grants: Greens $1Bn R&D Plan

In the Party’s headline economic announcement, the Greens have launched their plan to build a smarter, more innovative economy which has as its centrepiece an additional $1 billion of government investment in research and development (R&D) above current spend, including tax breaks for business. More>>

ALSO:

Inflation: CPI Increases 0.3 Percent In June Quarter

The consumers price index (CPI) rose 0.3 percent in the June 2014 quarter, Statistics New Zealand said today. This follows rises of 0.3 percent the March quarter and 0.1 percent in the December 2013 quarter. More>>

ALSO:

Get More From Scoop

 
 
Computer Power Plus

Standards New Zealand

Standards New Zealand
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news